Haemochromatosis is considered the commonest genetic disease in adults and affects ca. 1 in 1,000 Europeans. If untreated, haemochromatosis can cause fatigue, progress to cirrhosis, hepatocellular carcinoma, and joint disease. Early diagnosis and treatment can prevent these complications. In the light of recent progress in understanding the disease pathogenesis, and improvements in diagnosis, disease definitions had to be adjusted to appropriately to diagnose the disease, select patients for treatment and optimise treatment, counselling and follow up, which is all delivered in this new guideline. EASL has addressed the topic of haemochromatosis in previous Clinical Practice Guidelines of 2010, also published in the Journal of Hepatology. This 2022 publication is a profound revision of the previous CPGs.